Published in Blood Weekly, November 1st, 2001
Faith M. Uckun and colleagues at the Parker Hughes Institute in St. Paul, Minnesota, conducted a study to evaluate the efficacy of the "rationally designed [Janus kinase 3] JAK3 inhibitor WHI-P131", originally designed to treat Lou Gehrig disease, in a murine model.
In combination with other prophylactic drugs, WHI-P131 provided significant protection against GvHD, they found.
Uckun and coauthors administered 20...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.